Q4 2019 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q4 2019 Agios Pharmaceuticals Inc Earnings Conference Call
Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 Read more about Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation Read more about Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency Read more about Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) Read more about Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results Read more about Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer Read more about Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer
Agios Appoints Jonathan Biller as Chief Legal Officer Read more about Agios Appoints Jonathan Biller as Chief Legal Officer
Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma Read more about Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Read more about Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares